Clinical trials: MMR on 12 Month
Chickenpox
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
This study aims to assess the immune response and safety of GSK's candidate chickenpox and marketed MMR vaccines when given to children 12 to 15 months of age via a muscle injection.
- Trial name
- NCT06855160
- Testing
- Candidate varicella vaccine, Marketed varicella vaccine, MMR vaccine
- Where
- 22 sites in United States, Belgium and 5 more
- Volunteers
- 911 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
MMR on 12 Month
A Study on the Withdrawal of Second-generation Tyrosine Kinase Inhibitors After Dose Reduction in Patients With CML
patients with Ph+ CML-CP who have been treated with second-generation TKIs (nilotinib, dasatinib) for at least 3 years and maintains MMR for at least 2 years, continue to be treated with halved dose for 12 months, and then stop…
- Trial name
- NCT05341050
- Testing
- TKI
- Where
- 2 sites in China
- Volunteers
- 260 people
- Sponsor
- xuna
MMR on 12 Month
Withdrawal or Reduction TKIs in CML-CP
Compare MMR on 12 month treated with half TKIs(including imatinib, dasatinib, and nilotinib) or TKIs withdrawal.
- Trial name
- NCT04143087
- Testing
- withdrawal TKIs or halve TKIs
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Nanfang Hospital, Southern Medical University